LEADER 03323nam 2200613 a 450 001 9910808405203321 005 20240313154333.0 010 $a1-118-51700-8 010 $a1-299-24266-9 010 $a1-118-51701-6 035 $a(CKB)2670000000335822 035 $a(EBL)1132837 035 $a(OCoLC)829459871 035 $a(SSID)ssj0000833771 035 $a(PQKBManifestationID)11411977 035 $a(PQKBTitleCode)TC0000833771 035 $a(PQKBWorkID)10936154 035 $a(PQKB)10913476 035 $a(MiAaPQ)EBC1132837 035 $a(Au-PeEL)EBL1132837 035 $a(CaPaEBR)ebr10667420 035 $a(CaONFJC)MIL455516 035 $a(PPN)178990264 035 $a(EXLCZ)992670000000335822 100 $a20121126d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNonclinical safety assessment $ea guide to international pharmaceutical regulations /$fedited by William J. Brock, Kenneth L. Hastings, Kathy M. McGown 205 $a1st ed. 210 $aChichester, West Sussex $cJohn Wiley & Sons$d2013 215 $a1 online resource (487 p.) 300 $aDescription based upon print version of record. 311 $a0-470-74591-6 320 $aIncludes bibliographical references and index. 327 $aIntroduction to the development of drugs / Kathy McGown -- ICH / Ken Hastings -- USFDA / Bill Brock -- Latin America : MERCOSUR countries / Cristiana Leslie Corra -- Canada / Mark T. Goldberg -- EMEA / Adam Woolley -- Africa / Fariza Feraoun -- China / Lijie Fu -- Japan / Kazuichi Nakamura -- India / K.S. Rao -- Australia / Doug Francis -- Chronic repeat dose testing / Shana Azri-Meehan -- Carcinogenicity / James Popp -- Genotoxicity / Mark Powley -- Developmental and reproductive toxicology / Robert Parker -- Juvenile testing and pediatric claim / Melissa Tassinari -- Immunotoxicology / Leigh Ann Burns Naas -- Biologics / Chris Ellis -- Vaccines / Robert House -- Phototoxicity and photocarcinogenicity / Chris Sambuco -- Degradants, impurities excipients, and metabolites / Bob Osterberg. 330 $aBringing a new drug to market is a costly time-consuming process. Increased regional and international regulation over the last twenty years, while necessary, has only served to amplify these costs. In response to this escalation, developmental strategies have shifted towards a more global approach. In order to create the most cost-effective and safe processes, it is critical for those bringing drugs to market to understand both the globally accepted regulations and the local variations. Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations provides a practi 606 $aDrug development$xInternational cooperation 606 $aDrugs$xToxicology$xInternational cooperation 615 0$aDrug development$xInternational cooperation. 615 0$aDrugs$xToxicology$xInternational cooperation. 676 $a615.1/901 701 $aBrock$b William J$0292040 701 $aHastings$b Kenneth L$01603351 701 $aMcGown$b Kathy M$01603352 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910808405203321 996 $aNonclinical safety assessment$93927682 997 $aUNINA LEADER 02664oam 2200613I 450 001 9910148738503321 005 20240501152406.0 010 $a1-315-68075-0 010 $a1-317-39810-6 010 $a1-317-39811-4 024 7 $a10.4324/9781315680750 035 $a(CKB)3710000000922156 035 $a(MiAaPQ)EBC4729985 035 $a(OCoLC)966775553 035 $a(EXLCZ)993710000000922156 100 $a20180706d2017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 04$aThe impact of the First World War on international business /$fedited by Andrew Smith, Simon Mollan, and Kevin D. Tennent 205 $a1st ed. 210 1$aNew York ;$aLondon :$cRoutledge,$d2017. 215 $a1 online resource (301 pages) $cillustrations, tables 225 1 $aRoutledge International Studies in Business History 311 08$a1-138-34019-7 311 08$a1-138-93003-2 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $apt. 1. Shifting globalisation : Europe's hegemony challenged -- pt. 2. New opportunities : trans-border innovations in wartime -- pt. 3. Postwar reconstruction and its financing. 330 $aThe Impact of the First World War on International Business is the first book to focus on the impact of the WW1 on international business. It will explore the experiences of firms in Britain, France, Germany, Japan, China, and the United States covering a wide range of industries including financial services, mining, manufacturing, foodstuffs, and shipping. 410 0$aRoutledge international studies in business history. 606 $aInternational trade$xHistory$y20th century 606 $aInternational economic relations$xHistory$y20th century 606 $aInternational business enterprises$xHistory$y20th century 606 $aWorld War, 1914-1918$xEconomic aspects 606 $aEconomic history$y1750-1918 615 0$aInternational trade$xHistory 615 0$aInternational economic relations$xHistory 615 0$aInternational business enterprises$xHistory 615 0$aWorld War, 1914-1918$xEconomic aspects. 615 0$aEconomic history 676 $a338.8/809041 676 $a338.8809041 701 $aMollan$b Simon$f1977-$0865980 701 $aSmith$b Andrew$f1976-$0865981 701 $aTennent$b Kevin D$0865982 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910148738503321 996 $aThe impact of the First World War on international business$91932663 997 $aUNINA